Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk

Cancer Causes and Control

Volumn 21, Issue 10, 2010, Pages 1731-1741

  Lurie, Galina ^a   Terry, Kathryn L ^b   Wilkens, Lynne R ^a   Thompson, Pamela J ^a   McDuffie, Katharine E ^a   Carney, Michael E ^c   Palmieri, Rachel T ^d   Cramer, Daniel W ^b   Goodman, Marc T ^a  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF HAWAII   (United States)

^d IL   (United States)

Author keywords

Case control study; Epithelial ovarian cancer; Genetic polymorphism; Nonsteroidal antiinflammatory drugs; Prostaglandin endoperoxide synthase 2 (PTGS2) gene

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE 2; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; ARTICLE; CANCER INVASION; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; ETHNICITY; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HYSTERECTOMY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUESTIONNAIRE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2; FEMALE; GENOTYPE; HAWAII; HUMANS; LOGISTIC MODELS; MIDDLE AGED; NEW ENGLAND; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; YOUNG ADULT;

EID: 77956976649     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-010-9602-x     Document Type: Article

References (44)

1. N Auersperg AS Wong KC Choi SK Kang PC Leung 2001 Ovarian surface epithelium: biology, endocrinology, and pathology Endocr Rev 22 2 255 288 1:CAS:528:DC%2BD3MXjsFSntLs%3D 10.1210/er.22.2.255 11294827
2. MF Fathalla 1971 Incessant ovulation-a factor in ovarian neoplasia? Lancet 2 7716 163 1:STN:280:DyaE3M3ls12ltw%3D%3D 10.1016/S0140-6736(71)92335-X 4104488
3. LL Espey 1994 Current status of the hypothesis that mammalian ovulation is comparable to an inflammatory reaction Biol Reprod 50 2 233 238 1:CAS:528:DyaK2cXhvVeju78%3D 10.1095/biolreprod50.2.233 8142541
4. JS Richards DL Russell S Ochsner LL Espey 2002 Ovulation: new dimensions and new regulators of the inflammatory-like response Annu Rev Physiol 64 69 92 1:CAS:528:DC%2BD38XisFGms7Y%3D 10.1146/annurev.physiol.64.081501.131029 11826264
5. BN Ames MK Shigenaga TM Hagen 1993 Oxidants, antioxidants, and the degenerative diseases of aging Proc Natl Acad Sci USA 90 17 7915 7922 1:CAS:528:DyaK3sXmtVSksL4%3D 10.1073/pnas.90.17.7915 8367443
6. LJ Hofseth L Ying 2006 Identifying and defusing weapons of mass inflammation in carcinogenesis Biochim Biophys Acta 1765 1 74 84 1:CAS:528:DC%2BD2MXht12ku7%2FL 16169156
7. JM Schildkraut PG Moorman S Halabi B Calingaert JR Marks A Berchuck 2006 Analgesic drug use and risk of ovarian cancer Epidemiology 17 1 104 107 10.1097/01.ede.0000190538.55645.f8 16357602
8. AE Prizment AR Folsom KE Anderson 2010 Nonsteroidal anti-inflammatory drugs and risk for ovarian and endometrial cancers in the Iowa Women's Health Study Cancer Epidemiol Biomarkers Prev 19 2 435 442 1:CAS:528: DC%2BC3cXhs1eis7o%3D 10.1158/1055-9965.EPI-09-0976 20142241
9. A Tzonou A Polychronopoulou CC Hsieh A Rebelakos A Karakatsani D Trichopoulos 1993 Hair dyes, analgesics, tranquilizers and perineal talc application as risk factors for ovarian cancer Int J Cancer 55 3 408 410 1:STN:280:DyaK3szovVSitA%3D%3D 10.1002/ijc.2910550313 8375924
10. DW Cramer BL Harlow L Titus-Ernstoff K Bohlke WR Welch ER Greenberg 1998 Over-the-counter analgesics and risk of ovarian cancer Lancet 351 9096 104 107 1:STN:280:DyaK1c7gt1Klug%3D%3D 10.1016/S0140-6736(97)08064-1 9439495
11. A Akhmedkhanov P Toniolo A Zeleniuch-Jacquotte I Kato KL Koenig RE Shore 2001 Aspirin and epithelial ovarian cancer Prev Med 33 6 682 687 1:CAS:528:DC%2BD3MXosFGht70%3D 10.1006/pmed.2001.0945 11716667
12. JV Lacey Jr ME Sherman P Hartge A Schatzkin C Schairer 2004 Medication use and risk of ovarian carcinoma: a prospective study Int J Cancer 108 2 281 286 1:CAS:528:DC%2BD3sXhtVWgu73E 10.1002/ijc.11538 14639616
13. A Tavani S Gallus VC La E Conti M Montella S Franceschi 2000 Aspirin and ovarian cancer: an Italian case-control study Ann Oncol 11 9 1171 1173 1:STN:280:DC%2BD3crgvFWnuw%3D%3D 10.1023/A:1008373616424 11061614
14. CG Hannibal MA Rossing KG Wicklund KL Cushing-Haugen 2008 Analgesic drug use and risk of epithelial ovarian cancer Am J Epidemiol 167 12 1430 1437 10.1093/aje/kwn082 18390840
15. SP Pinheiro SS Tworoger DW Cramer BA Rosner SE Hankinson 2009 Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts Am J Epidemiol 169 11 1378 1387 10.1093/aje/kwp062 19342401
16. KD Crew AI Neugut 2006 Aspirin and NSAIDs: effects in breast and ovarian cancers Curr Opin Obstet Gynecol 18 1 71 75 10.1097/01.gco.0000192972.54105.cf 16493264
17. WL Smith RM Garavito DL DeWitt 1996 Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2 J Biol Chem 271 52 33157 33160 1:CAS:528:DyaK2sXitFaksg%3D%3D 10.1074/jbc.271.52.33157 8969167
18. RN DuBois SB Abramson L Crofford, et al. 1998 Cyclooxygenase in biology and disease FASEB J 12 12 1063 1073 1:CAS:528:DyaK1cXlvFWntbY%3D 9737710
19. CN Landen Jr SP Mathur MS Richardson WT Creasman 2003 Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies Am J Obstet Gynecol 188 5 1174 1176 1:CAS:528:DC%2BD3sXktFWhurs%3D 10.1067/mob.2003.284 12748469
20. K Shigemasa X Tian L Gu Y Shiroyama N Nagai K Ohama 2003 Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas Int J Oncol 22 1 99 105 1:CAS:528:DC%2BD3sXhsVSnsA%3D%3D 12469191
21. I Khalifeh AR Munkarah F Lonardo, et al. 2004 Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma Int J Gynecol Pathol 23 2 162 169 10.1097/00004347-200404000-00011 15084845
22. S Li K Miner R Fannin BJ Carl BJ Davis 2004 Cyclooxygenase-1 and 2 in normal and malignant human ovarian epithelium Gynecol Oncol 92 2 622 627 1:CAS:528:DC%2BD2cXptV2qtw%3D%3D 10.1016/j.ygyno.2003.10.053 14766256
23. SJ Cok AR Morrison 2001 The 3′-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency J Biol Chem 276 25 23179 23185 1:CAS:528:DC%2BD3MXkvValsrs%3D 10.1074/jbc.M008461200 11294846
24. DA Dixon CD Kaplan TM McIntyre GA Zimmerman SM Prescott 2000 Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3′-untranslated region J Biol Chem 275 16 11750 11757 1:CAS:528:DC%2BD3cXisl2js78%3D 10.1074/jbc.275.16.11750 10766797
25. H Yang J Gu X Lin, et al. 2008 Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition Clin Cancer Res 14 7 2236 2244 1:CAS:528:DC%2BD1cXkt1arsrc%3D 10.1158/1078-0432.CCR- 07-1670 18381966
26. KR Cho I Shih 2009 Ovarian cancer Annu Rev Pathol 4 287 313 1:CAS:528:DC%2BD1MXis1aiu7k%3D 10.1146/annurev.pathol.4.110807.092246 18842102
27. SC Mok J Kwong WR Welch, et al. 2007 Etiology and pathogenesis of epithelial ovarian cancer Dis Markers 23 5-6 367 376 1:CAS:528: DC%2BD2sXhtlGjtL7I 18057520
28. M Mandai K Yamaguchi N Matsumura T Baba I Konishi 2009 Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management Int J Clin Oncol 14 5 383 391 10.1007/s10147-009-0935-y 19856044
29. F Chiaffarino F Parazzini C Bosetti, et al. 2007 Risk factors for ovarian cancer histotypes Eur J Cancer 43 7 1208 1213 10.1016/j.ejca.2007.01.035 17376671
30. MA Gates BA Rosner JL Hecht SS Tworoger 2010 Risk factors for epithelial ovarian cancer by histologic subtype Am J Epidemiol 171 1 45 53 10.1093/aje/kwp314 19910378
31. A Berchuck JM Schildkraut CL Pearce G Chenevix-Trench PD Pharoah 2008 Role of genetic polymorphisms in ovarian cancer susceptibility: development of an international ovarian cancer association consortium Adv Exp Med Biol 622 53 67 10.1007/978-0-387-68969-2-5 18546618
32. KL Terry VI De L Titus-Ernstoff MC Shih DW Cramer 2005 Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk Cancer Res 65 13 5974 5981 1:CAS:528:DC%2BD2MXlslOqt7c%3D 10.1158/0008-5472.CAN-04-3885 15994977
33. KH Tung MT Goodman AH Wu, et al. 2003 Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study Am J Epidemiol 158 7 629 638 10.1093/aje/kwg177 14507598
34. MG Backlund JR Mann RN DuBois 2005 Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2 Oncology 69 Suppl 1 28 32 1:CAS:528:DC%2BD2MXhtVymt73I 10.1159/000086629 16210874
35. MJ Thun 2000 Beyond willow bark: aspirin in the prevention of chronic disease Epidemiology 11 4 371 374 1:STN:280:DC%2BD3M%2FhsVKhsg%3D%3D 10.1097/00001648-200007000-00001 10874540
36. NR Cook IM Lee JM Gaziano, et al. 2005 Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial JAMA 294 1 47 55 1:CAS:528:DC%2BD2MXlvVKnt7Y%3D 10.1001/jama.294.1.47 15998890
37. EH Awtry J Loscalzo 2000 Aspirin Circulation 101 10 1206 1218 1:CAS:528:DC%2BD3cXit1aksL0%3D 10715270
38. J Cuzick F Otto JA Baron, et al. 2009 Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement Lancet Oncol 10 5 501 507 1:CAS:528:DC%2BD1MXlsVKhs78%3D 10.1016/S1470-2045(09)70035-X 19410194
39. JD Potter 1999 Colorectal cancer: molecules and populations J Natl Cancer Inst 91 11 916 932 1:STN:280:DyaK1M3os1WjsQ%3D%3D 10.1093/jnci/91.11.916 10359544
40. C Denkert M Kobel S Pest, et al. 2002 Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma Am J Pathol 160 3 893 903 1:CAS:528:DC%2BD38XisVemtrk%3D 11891188
41. A Munkarah R Ali-Fehmi 2005 COX-2: a protein with an active role in gynecological cancers Curr Opin Obstet Gynecol 17 1 49 53 15711411
42. E Ozel HE Pestereli T Simsek G Erdogan FS Karaveli 2006 Expression of cyclooxygenase-2 and inducible nitric oxide synthase in ovarian surface epithelial carcinomas: is there any correlation with angiogenesis or clinicopathologic parameters? Int J Gynecol Cancer 16 2 549 555 1:STN:280:DC%2BD283lslyntw%3D%3D 10.1111/j.1525-1438.2006.00567.x 16681724
43. S Uddin M Ahmed A Hussain, et al. 2010 Cyclooxygenase-2 inhibition inhibits PI3 K/AKT kinase activity in epithelial ovarian cancer Int J Cancer 126 2 382 394 1:CAS:528:DC%2BD1MXhsFGjsrvE 10.1002/ijc.24757 19621391
44. SS Seo YS Song DH Kang, et al. 2004 Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer Gynecol Oncol 92 3 927 935 1:CAS:528: DC%2BD2cXhsVOnsL8%3D 10.1016/j.ygyno.2003.11.055 14984962